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Abstract
Deubiquitinating enzymes (DUBs) are involved in the regulation of distinct critical cellular processes. Ubiquitin C-terminal
Hydrolase L1 (UCH L1) has been linked to several neurological diseases as well as human cancer, but the physiological
targets and the regulation of UCH L1 expression in vivo have been largely unexplored. Here we demonstrate that UCH L1
up-regulates b-catenin/TCF signaling: UCH L1 forms endogenous complexes with b-catenin, stabilizes it and up-regulates b-
catenin/TCF-dependent transcription. We also show that, reciprocally, b-catenin/TCF signaling up-regulates expression of
endogenous UCH L1 mRNA and protein. Moreover, using ChIP assay and direct mutagenesis we identify two TCF4-binding
sites on the uch l1 promoter that are involved in this regulation. Since the expression and deubiquitinating activity of UCH
L1 are required for its own basic promoter activity, we propose that UCH L1 up-regulates its expression by activation of the
oncogenic b-catenin/TCF signaling in transformed cells.
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Introduction
The lifetime of many central components of intracellular
signaling is regulated by the ubiquitin system [1]. Among them
is the multifunctional molecule b-catenin, which plays a dual role
in cells as a major structural component of cell–cell adherens
junctions and as a signaling molecule in the Wnt pathway [2,3]. As
a part of the transcriptional machinery b-catenin provides a
transactivation domain in a heterodimeric complex with TCF/Lef
transcription factors [4]. b-catenin/TCF/Lef-dependent tran-
scription induces expression of genes such c-myc, cyclin D, c-jun,
survivin and others, which indicates that b-catenin/TCF/Lef
signaling up-regulates oncogenic cellular pathways [5].
The nonjunctional pool of b-catenin is normally a target for
destruction by the ubiquitin-proteasome system, and the process of
b-catenin regulation through ubiquitination has been studied
intensively [6]. The reverse process - deubiquitination–has also
been implicated in the regulation of b-catenin intracellular levels
[7], and the deubiquitinating enzyme Fam/USP9X was identified
as a candidate for b-catenin stabilization [8].
Among the large family of DUBs are Ubiquitin C-terminal
Hydrolases–cysteine hydrolases that contain the typical active site
triad of cysteine, histidine, and aspartic acid and that catalyze
hydrolysis of C-terminal esters and amides of ubiquitin [9]. One of
them - UCH L1 - is abundantly (up to 2% of the total soluble
protein) expressed innormal braintissue,and mutationsinthe UCH
L1 gene have been associated with Parkinson’s and Alzheimer’s
diseases [10,11]. In addition to its deubiquitinating activity, UCH L1
has been shown to exhibit dimerization-dependent ubiquitin ligase
activity [12]. Another function of UCH L1 in neurons involves
binding and stabilizing mono-ubiquitin in vivo, and this function is
independent of the enzymatic activity of UCH L1 [13].
There is also growing evidence indicating that UCH L1 is
overexpressed in a number of cancers [14,15,16,17,18,19], which
might be associated with a poor prognosis in some of these
cancers. Recent data support this hypothesis, implicating UCH L1
in the up-regulation of metastasis in non-small cell lung cancer
[20], and in the proliferation and invasive capacity of malignant B-
cells [21]. The possible involvement of UCH L1 in the
pathogenesis and progression of human cancer raises the question
of how expression of UCH L1 is regulated in transformed cells.
The minimal promoter of the uch l1 gene was cloned and partially
characterized in neurons [22,23,24], and B-Myb, a transcription
factor implicated in the regulation of cell cycle [25], has been
shown to stimulate expression of murine uch l1 on the promoter
level in vitro and in vivo [26], but the regulation of uch l1 expression
in cancer cells is still largely unexplored.
Here we demonstrate a positive feedback between UCH L1 and
oncogenic b-catenin/TCF signaling, providing evidence that in
transformed cells UCH L1 up-regulates its own expression
through b-catenin/TCF-dependent transcription.
Results and Discussion
Previously we have demonstrated that in virus-transformed B-
cells b-catenin is physically associated with an active DUB with a
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e5955molecular weight of ,26 kDa, and proposed that this DUB is
UCH L1 [7,27]. To verify this suggestion, we immunoprecipitated
with specific antibodies endogenous UCH L1 and b-catenin from
lymphoid KR4 and epithelial 293 cells. Western blots of IPs
(Fig. 1A) demonstrate that b-catenin and UCH L1 form
endogenous complexes in cell lines of different origin. Addition-
ally, we performed immunofluorescent co-staining of endogenous
and overexpressed b-catenin and UCH L1 in 293 cells (Fig. 1B).
UCH L1 and b-catenin were predominantly co-localized in the
nucleus, although some cytoplasmic staining for UCH L1 was also
observed (Fig. 1B, left).
Similar staining was observed in A-431 carcinoma cell line
(http://www.proteinatlas.org/cell_if_unit.php?antibody_id=
5993&mainannotation_id=200003070). Co-immunostaining
with HA and myc antibodies after co-transfection with HA-UCH
L1 and myc-b-catenin expression vectors revealed similar, mostly
nuclear co-localization of overexpressed UCH L1 and b-catenin
(Fig. 1B, right). Nuclear localization of UCH L1 (PGP9.5) was also
observed in lung cancer cell line H1299, where UCH L1 can bind
Jab1/Kip1 complexes [28].
The conserved cysteine 90 and histidine 161 in UCH L1 are the
necessary catalytic residues for its deubiquitinating activity [9]. We
attempted to determine whether the deubiquitinating activity of
UCH L1 is important for its ability to form a complex with b-
catenin. After overexpression of HA-UCH L1 wild type and
mutants C90S and H161D (with cysteine 90 and histidine 161
converted to serine and aspartic acid, respectively [9]), UCH L1
was immunoprecipitated from the cells and the precipitates probed
with b-catenin antibody (Fig. 1C, left). Deubiquitinating activity of
overexpressed HA-UCH L1 proteins was tested by hydrolysis of
the Ub-AMC substrate, which confirmed that enzymatic activity
of both C90S and H161D was impaired (Fig. 1C, right). The
results indicate that b-catenin is associated preferentially with wild
type UCH L1, but not with enzymatically inactive UCH L1
Figure 1. UCH L1 is physically associated with b-catenin. A. Endogenous b-catenin or UCH L1 were immunoprecipitated from KR4 (left) and
293 (right) cells. IPs were resolved in 10–12% PAGE and probed with indicated antibodies. Mouse and rabbit normal immunoglobulins were used as
controls for IPs. B. Left panel: nuclear co-localization of UCH L1 and b-catenin. 293 cells were fixed in 4% PFA and double-immunostained with UCH
L1 and b-catenin antibodies and red and green fluorescent secondary antibodies. Right panel: 293 cells were transfected with wild type HA-UCH L1
and myc-b-catenin expression vectors. After 24 h cells were fixed and probed with HA and myc antibodies. C. b-catenin is associated with wild type
UCH L1, but not with inactive UCH L1 mutants. 293 cells were transfected with wild type and HA-UCH L1 mutants C90S and H161D, and UCH L1 was
immunoprecipitated with HA antibody 48 h after transfection. IPs were resolved in 12% PAGE, transferred to PVDF membrane and probed with b-
catenin antibody. Enzymatic activity of UCH L1 mutants was verified by in vitro hydrolysis of Ub-AMC (right panel).
doi:10.1371/journal.pone.0005955.g001
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is required for the molecular events that precede its association
with b-catenin.
To investigate the possible role of UCH L1 expression in the
regulation of b-catenin levels, we created 293 cell lines stably
expressing two different UCH L1 siRNAs (see Material and
Methods). As shown in Fig. 2A, the inhibition of UCH L1 protein
expression correlates with reduction of b-catenin levels. To
determine whether UCH L1 expression affects b-catenin ubiqui-
tin-dependent proteasomal degradation, we immunoprecipitated
endogenous b-catenin from control and UCH L1 siRNA-
expressing cells in the presence or absence of the proteasome
inhibitor MG101 (Fig. 2B). Western blot analysis demonstrates
that while without the inhibitor the amount of b-catenin is reduced
in UCH L1 siRNA-expressing cells (compare lanes 3 and 5 to lane
1), the amount of accumulated b-catenin in the presence of
MG101 is greater in the cells where UCH L1 expression is
inhibited (compare lanes 4 and 6 to lane 2). These results indicate
the involvement of UCH L1 in the regulation of b-catenin
ubiquitination, and suggest the possibility of direct deubiquitina-
tion of b-catenin by UCH L1. To test this possibility, we used in
vitro-translated and in vitro-ubiquitinated b-catenin (Fig. 2C, lanes 4
and 1) as substrate for UCH L1. As shown in Fig. 2C, lanes 2 and
3, the addition of purified UCH L1 results in the disappearance of
Figure 2. UCH L1 up-regulates b-catenin signaling. A. Reduction of expression of UCH L1 correlates with decrease in b-catenin
protein levels. 293 cells were transfected with control GFP siRNA or two UCH L1 siRNAs in pRS vector and maintained in medium containing
puromycin. After 3 weeks of selection total lysates from control- and si1/2 UCH L1-transfected cells were resolved in 12% PAGE, transferred to PVDF
membrane and probed with b-catenin and UCH L1 antibodies. B. More b-catenin accumulates in UCH L1 siRNA-expressing cells in the
presence of proteasome inhibitor. Stable 293 cell lines expressing control and UCH L1 siRNAs were treated for 4 h with 25 mM MG101 or DMSO
as negative control. b-catenin was immunoprecicpitated from total lysates, IPs were resolved in 10% PAGE and probed with b-catenin antibodies.
Mouse normal immunoglobulins were used as control for IPs. Arrow heads indicate ubiquitinated forms of b-catenin. C. UCH L1 is involved in
deubiquitination of b-catenin in vitro. b-catenin was in vitro-translated (lane 4) as described in Material and Methods. To induce further
ubiquitination equal amounts of translated b-catenin were pre-incubated with Ub mix for 30 min, and an in-vitro deubiquitination reaction was
carried out in the absence (lane 1) or presence of 2 or 4 mM recombinant UCH L1 (lanes 2 and 3). Western blot was performed with b-catenin
antibody. D. Deubiquitinating activity of UCH L1 is required for TCF4 transcriptional activity. UCH L1 wild type or UCH L1 inactive
mutants C90S and H161D were co-transfected with either TOPFlash or FOPFlash into 293 and 3T3 cells. Luciferase activity and expression of HA-UCH
L1 proteins were determined 48 h post-transfection. Where indicated, cells were treated with 25 mM LiCl 6 h before harvesting. The data represent
two independent experiments prepared in triplicate and normalized to FOPFlash activity.
doi:10.1371/journal.pone.0005955.g002
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catenin as a plausible substrate for UCH L1, although they do not
eliminate the possibility that UCH L1 effects b-catenin degrada-
tion indirectly. For example, deubiquitination of other targets
could result in impaired ubiquitination or proteasomal degrada-
tion of b-catenin in both in vivo and in vitro systems. Nevertheless,
the observation that b-catenin levels depend on UCH L1
expression raised the question of whether UCH L1 affects b-
catenin’s function as a transcriptional co-activator.
To examine this possibility, we used luciferase reporter assays to
analyze b-catenin/TCF transcriptional activity (Fig. 2D). We
utilized HEK 293 and NIH 3T3 cells expressing high and low
levels of endogenous UCH L1, which were confirmed by RT-PCR
with UCH L1 specific primers (Fig. 2D, right). The cells were co-
transfected with reporter plasmids containing binding sites for
TCF [29] (see Materials and Methods), along with wild type and
enzymatically inactive UCH L1 mutants (expression of UCH L1
proteins was confirmed by western blot with HA antibody, Fig. 2D,
top panel). As a positive control for activation of b-catenin-
dependent transcription, we used the GSK3b pharmacological
inhibitor, LiCl [30]. Overexpression of wild type UCH L1 had
very little, if any, effect on the basic or LiCl-induced b-catenin/
TCF transcriptional activity in 293 cells (Fig. 2D, left), but in 3T3
cells, the expression of wild type UCH L1 increased b-catenin/
TCF transcription significantly (Fig. 2D, right). These results
might be explained by different endogenous levels of UCH L1 in
293 and 3T3 cells: so that additional overexpression could not add
much to b-catenin/TCF activity in 293 cells, whereas in 3T3 cells
which have very low endogenous UCH L1, the effect of exogenous
UCH L1 on b-catenin/TCF signaling was more profound.
Importantly, expression of the DUB-inactive mutants of UCH
L1 C90S and H161D inhibited b-catenin/TCF reporter activity in
both cell lines (Fig. 2D), indicating that b-catenin/TCF transcrip-
tional activity depends on the deubiquitinating activity of UCH
L1.
Additional information supporting the hypothesis of UCH L1-
dependent regulation of b-catenin/TCF signaling was provided
from gene expression profiling of stable 293 cell lines expressing
control and UCH L1 siRNA: inhibition of UCH L1 reveals
reduced expression of several known physiological targets of b-
catenin/TCF transcriptional activity such as c-myc, cyclin D1,
fibronectin and stromelysin (Bheda. A, unpublished data).
The observation that UCH L1 expression is elevated in
malignant tumor cells indicates that the uch l1 gene might be
subject to transcriptional regulation during cellular transformation
by oncogenic pathways such as b-catenin/TCF. Analysis of the
uch l1 promoter using Patch 1.0 has revealed two 59-TTTGA-39
putative Lef-1 binding sites on the negative strand [31], pointing to
the b-catenin/TCF/Lef complex as a candidate for uch l1 gene
regulation. To examine this possibility, we utilized a reporter
construct carrying the luciferase gene under the direction of the 59
minimal promoter (see Materials and Methods) of the human uch
l1 gene [23].
First, we have analyzed uch l1 promoter activity in cell lines
stably expressing UCH L1 siRNAs: if our hypothesis about b-
catenin/TCF-dependent regulation of uch l1 is right, then UCH
L1 expression should affect its own promoter activity. Indeed, as
shown in Fig. 3A, uch l1 promoter (Uchl1p-Luc) activity is
significantly lower in cells with a reduced amount of UCH L1. To
determine whether UCH L1 deubiquitinating activity is required
for its promoter activity we overexpressed wild type and inactive
UCH L1 mutants along with the Uchl1p-Luc reporter in control
293 cells (Fig. 3B). Although UCH L1 proteins were expressed at
similar levels, uch l1 promoter activity was much lower in the
presence of C90S and H161D UCH L1 mutants, indicating that
the deubiquitinating activity of UCH L1 is necessary for its
promoter activation.
To determine whether b-catenin/TCF transcription up-regu-
lates the uch l1 promoter, we tested Flag-tagged TCF4 wild type
and a transcriptionaly inactive N-terminal deletion mutant (dN-
TCF4) unable to bind b-catenin [32], for their ability to affect
Uchl1p-Luc reporter activity in the presence or absence of the b-
catenin activator LiCl in 293 cells (high levels of endogenous UCH
L1) and 3T3 cells (low endogenous levels) (Fig. 3C). Overexpres-
sion of wild type TCF4 alone had little stimulatory effect on the
uch l1 promoter in both cell lines, but wt-TCF4 significantly
increased LiCl-dependent activation of uch l1 promoter with a
much more profound effect in 3T3 than in 293 cells. Results in
Fig. 3C, also demonstrate that the N-terminal deletion mutant of
TCF4 inhibited uch l1 promoter activity in both cell lines, even in
the presence of LiCl (expression levels of wt-TCF4 and dN-TCF4
were confirmed by western blot (Fig. 3C, top)). Together, these
results indicate that TCF4 up-regulates the uch l1 promoter and
the effect depends on its ability to bind b-catenin.
To confirm the role of b-catenin signaling in the up-regulation
of endogenous UCH L1 expression, we employed two different
approaches. First, inhibition of b-catenin expression by transient
transfection of b-catenin siRNAs in 293 cells (expressing high
levels of UCH L1): Fig. 3D shows that a reduction of b-catenin
expression by both siRNAs resulted in decreased levels of
endogenous UCH L1 protein. Second, activation of b-catenin
signaling in 3T3 cells (express very low levels of UCH L1) by
25 mM LiCl for 24 hours: Fig. 3E demonstrates that the
activation of b-catenin with LiCl results in a significant increase
of both endogenous UCH L1 RNA (Fig. 3E, left) and protein
(Fig. 3E, right) levels.
To determine whether the b-catenin/TCF complex up-
regulates UCH L1 expression through direct binding to its
promoter, we performed a ChIP assay using the TCF4 antibody
followed by DNA isolation and PCR with primers for both
putative TCF/Lef sites on the uch l1 promoter in lymphoid KR4
and epithelial 293 cells (Fig. 4A). Non-immunoprecipitated
chromatin was used as an input control and normal IgG as a
negative control. In lymphoid KR4 cells, TCF4 binding to both
putative sites on the uch l1 promoter was detected without
additional treatment (Fig. 4A, left); however in 293 cells TCF4-
DNA binding was clearly observed after additional activation of b-
catenin with LiCl (Fig. 4A, right).
To verify the significance of the putative TCF/Lef binding sites
for b-catenin/TCF-dependent activation of the uch l1 promoter,
we mutated each of two sites in the promoter, as well as both sites
using the wild type uch l1 promoter reporter (UCHL1p-WT) as a
template. We transiently transfected wild type and mutant
reporters into 3T3 cells and compared their activities (Fig. 4B).
To activate b-catenin/TCF signaling, we used co-expression of
wild type TCF4, treatment with LiCL, or the combination of both.
TCF4 itself was able to activate only UCHL1p-WT, but not any of
the three mutant reporters (Fig. 4B, second column in each group).
In the presence of LiCl, mutations in each putative TCF/Lef site
resulted in a decrease of the promoter activity (Fig. 4B, third
column in each group). The combination of TCF4 and LiCl had
the strongest cumulative effect on the wild type promoter
(UCHL1p-WT). Mutations in each (with a slightly more profound
effect on the double-mutant) putative TCF/Lef binding site
significantly reduced TCF4/LiCl-dependent activation of Uchl1p-
Luc reporters (Fig. 4B, fourth column of each group). Taken
together these results identify the uch l1 promoter as a direct target
of b-catenin/TCF/Lef transcriptional activity. It is worth noticing,
Catenin/TCF and UCH L1
PLoS ONE | www.plosone.org 4 June 2009 | Volume 4 | Issue 6 | e5955Figure 3. UCH L1 regulates its promoter activity through b-catenin/TCF signaling. A. Expression of UCH L1 is necessary for its
promoter activity. Stable 293 cell lines expressing control GFP siRNA and two UCH L1 siRNAs were co-transfected with Uchl1p-Luc reporter plasmid
(see Materials and Methods); 48 h post-transfection luciferase activity was measured and normalized to b-gal activity. Reduction in UCH L1 expression
was verified by Western blotting. B. Deubiquitinating activity of UCH L1 is required for its promoter activity. Wild type UCH L1 or UCH L1
mutants C90S and H161D expression vectors were transfected into 293 cells along with Uchl1p-Luc reporter. Luciferase assays were performed 24 h
post-transfection. The data represent two independent experiments prepared in triplicate and normalized to b-gal activity. C. b-catenin-binding N-
terminus of TCF4 is required for TCF4-dependent activation of UCH L1 promoter. Wild type or deltaN TCF4 expression vectors were co-
transfected along with Uchl1p-Luc reporter into 293 (left) and 3T3 (right) cells. Luciferase activity and expression of Flag-TCF4 proteins was
determined. Where indicated, cells were treated with 25 mM LiCl 6 hour before harvesting. The data represent two independent experiments
prepared in triplicate and are normalized for b-gal activity. D. Reduction of b-catenin expression decreases UCH L1 protein levels. 293 cells
were transiently transfected with two b-catenin siRNAs in pSUPER.retro vector. Protein levels of b-catenin and UCH L1 were determined by Western
blotting 48 h post-transfection. E. Treatment with LiCl induces UCH L1 expression in 3T3 cells. Cells were treated with 25 mM LiCl for 24 h,
total RNA isolated, and real-time PCR analysis with specific primers for UCH L1 was performed (left). Total lysates from the same cells were separated
in 12% PAGE, transferred to PVDF membrane and probed with UCH L1 antibody (right).
doi:10.1371/journal.pone.0005955.g003
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PLoS ONE | www.plosone.org 5 June 2009 | Volume 4 | Issue 6 | e5955Figure 4. TCF/Lef factors up-regulate UCH L1 expression through direct binding to its promoter. A. TCF4 binds to endogenous uch
l1 promoter. ChIP/PCR analysis was performed to determine binding of TCF4 factor to two putative binding sites on uch l1 promoter (left) with the
use of specific TCF4 antibody in KR4 or 293 cells treated with 25 mM LiCl. Normal IgGs were used as a negative controls in IPs. PCR reactions were
performed with primers targeting TCF4 binding sites on the uch l1 promoter (see Materials and Methods), and amplified DNA products were resolved
in 2% agarose gel. B. Mutations in TCF/Lef putative sites inhibit b-catenin/TCF4-dependent activation of the uch l1 promoter. Site-
directed mutagenesis of TCF/Lef binding sites was performed as described in Materials and Methods. 3T3 cells were transfected with Uchl1p-Luc wild
type and mutant reporter plasmids in the presence or absence of TCF4 expression vector. Luciferase assays were performed 48 h post-transfection
and are normalized to b-gal activity. Where indicated 25 mM LiCl was added to the cells 6 h before harvesting. Expression of TCF4 was confirmed by
Western blotting.
doi:10.1371/journal.pone.0005955.g004
Catenin/TCF and UCH L1
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l1 promoter reduce promoter activity in the presence of LiCl, they
do not reduce activity to the basal level. Since LiCl activates b-
catenin by inhibition of GSK3b [33], the result suggests that other
GSK3b-dependent pathways are involved in the regulation of the
uch l1 promoter, in addition to b-catenin/TCF signaling.
While the roles of the multifunctional molecule b-catenin in
normal and cancer cells have been studied intensively, the
potential impact of UCH L1 in oncogenesis is largely unexplored.
Moreover, information on UCH L1 expression in different cancer
cell lines is contradictory: on the one hand, silencing of UCH L1
expression by the methylation of its promoter was observed in
some cancer cell lines and primary tumors [34,35,36]. On the
other hand, there is growing evidence indicating that UCH L1 is
overexpressed in a number of cancers [14,15,16,17,18,19,37],
including recent data demonstrating the invasive capacity of
malignant cells conferred by UCH L1 [20,21]. The observation
that expression and enzymatic activity of UCH L1 are required for
its basic promoter activity opens speculation that as a deubiqui-
tinating enzyme, UCH L1 might directly or indirectly regulate
activity of different transcription factors involved in the regulation
of its own promoter. Studies on UCH L1 functions in normal and
cancer cells have just begun, and the physiological roles of this
molecule in oncogenesis are unknown. Our recent studies
demonstrate that proliferation and migration of cell lines stably
expressing UCH L1 siRNAs is reduced, and the sensitivity to
apoptotic agents was increased [38].
UCH L1 appears to be a multi-functional protein that might
contribute to more diverse cellular processes than were previously
thought. Our results indicate that UCH L1 and b-catenin/TCF
can positively regulate each other (Fig. 5), supporting the
hypothesis that UCH L1 has oncogenic potential, at least under
some circumstances.
Materials and Methods
Cell Lines and Reagents
Human 293 embryonic kidney cells and NIH 3T3 mouse
fibroblast cells were cultured in DMEM (Sigma) supplemented
with 10% FBS (Sigma) and penicillin–streptomycin. Lymphoblas-
toid cell line KR4 [39] were cultured in RPMI 1640 medium plus
10% FBS and penicillin–streptomycin. All cells were maintained at
37uCi n5 %C O 2 in air. MG101, recombinant UCH L1, LiCl and
Ubiquitin-AMC were purchased from Calbiochem, Boston
Biochem, Sigma and Biomol respectively.
Expression Plasmids
Wild-type pcDNA3-HA-UCH L1 was a gift from Dr. P. T.
Lansbury. pcDNA3-HA-UCH L1 C90S and H161D mutants
were generated by inserting a specific mutation at the Cys 90 and
H161 sites in wild-type pcDNA3-HA-UCH L1 plasmid with the
use of the Quik-Change Site Directed Mutagenesis Kit following
the manufacturer’s instructions (Stratagene). UCH L1 siRNA was
obtained from OriGene Technologies, Inc, in the form of a
shRNA expression plasmid. The control siRNA targeted against
GFP and was also obtained from OriGene Technologies, Inc.
pSuper-retro b-catenin siRNA was constructed as described by the
manufactor. TCF reporter plasmids, TOPFlash (optimal TCF-
binding site) and FOPFlash (mutated TCF-binding site) were
obtained from Upstate Biotechnology. Wild type and deltaN
Figure 5. Working hypothesis: UCH L1 up-regulates its expression through b-catenin/TCF signaling. UCH L1 stabilizes b-catenin through
deubiquitination and up-regulates b-catenin/TCF transcriptional activity. TCF4/Lef1 transcription factors directly bind to the uch l1 promoter and up-
regulate UCH L1 RNA and protein expression.
doi:10.1371/journal.pone.0005955.g005
Catenin/TCF and UCH L1
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Clevers. The UCH L1 promoter region [22] was PCR-amplified
from human genomic DNA and cloned into Kpn I and Hind III
sites of pGL3 basic plasmid and confirmed by sequencing. The
siRNA or primers used in the experiments are as follows:
UCH L1 siRNA–1: 59TGTGGCACAATCGGACTTATT-
CACGCAGT 39
UCH L1 siRNA–2: 59 CCATGATGCCGTGGCACAGGA-
AGGCCAAT 39
b-Catenin siRNA–1: 59CCATGGAACCAGACAGAAA 39
b-Catenin siRNA–2: 59CCCACTAATGTCCAGCGTT 39
UCH L1 promoter–KpnI: 59GGTACCAAAACGAACCT-
CGGTACTGG
UCH L1 promoter–Hind III: 59AAGCTTCTCACCTCGG-
GGTTGATCT
Immunofluorescence staining
293 cells were grown on poly-L-Lysine (Sigma)-coated cover-
slips in 12-well dishes until 75% confluent. The cells were washed
with PBS, fixed with 4% paraformaldehyde for 10 min, permea-
blized with 0.5% triton, washed three times with PBS and blocked
with 5% normal donkey serum. Cells were then incubated with
rabbit anti-UCH L1 antibody (Zymed, 1:100), mouse anti-b-
catenin antibody (Zymed, 1:100), rabbit anti-HA (Santa Cruz,
1:500), mouse anti-myc (Santa Cruz, 1:250) in 1:5 dilution of
blocking solution for 1 h at 37uC and then washed three times
with PBS. Next, cells were incubated with Alexafluor-594-
conjugated goat anti-rabbit and Alexafluor-488-conjugated goat
anti-mouse antibodies (Vector Laboratories, 1:500) for 1 h at
37uC, washed four times with PBS and mounted. Fluorescent
images were created using Openlab software (Improvision Inc,
MA, USA).
Immunoblot
Total cell lysates or immunocomplexes were resolved on SDS-
PAGE, transferred to nitrocellulose membrane (Osmonics),
blocked in 5% milk-Tris-buffered saline solution, and incubated
at 4uC overnight with b-catenin (1:1000, BD Transduction
Laboratories, ), UCH L1 (1:7500, Zymed), GAPDH (1:5000,
Sigma) antibodies. After washing with TBST for 10 min three
times, the membrane was incubated with appropriate secondary
antibody at room temperature for 1 h, washed three times with
TBST as before, treated with SuperSignal (Pierce) detection
reagents, and exposed to Kodak XAR-5 film.
Immunoprecipitation
Cells were lysed with buffer containing of 50 mM, pH 7.6 Tris-
HCl, 1% NP-40, 0.25% Na-deoxycholate, 1 mM EDTA, 1 mM
Na3VO4, 1 mM NaF and complete protease inhibitor mixture
(Roche Diagnostics). After pre-clearing, cell lysates were incubated
with b-catenin (Zymed) or UCH L1 antibody (Zymed) or control
Ig G for 1 h in 4uC; immune complexes were then incubated with
protein A/G Sepharose beads (Santa Cruz) at 4uC overnight,
washed four times with protein lysis buffer, and then eluted from
the protein G-Sepharose with 26Laemmli’s buffer by boiling for
3 min.
In vitro Deubiquitination Assays
Endogenous b-catenin was immunoprecipitated from 293 cells
treated with 25 mM MG101 for 3 h with specific or control
antibodies. Exogenous b-catenin protein was translated in a TNT-
coupled reticulocyte-lysate system (Promega) with pCMV b-catenin
as template. In-vitro translated b-catenin (2 ml) was pre-incubated
with 10 mM DTT for 15 min and for 2 h at 30uCi n2 0mlo fU b
reaction mixture containing: 50 mM Tris-HCl (pH 7.5), 50 mM
NaCl, 2 mM Mg-ATP, 20 mM mammalian ubiquitin, 25 mM
MG101, 100 nM rabbit E1 and 3 mlr e t i c u l o c y t el y s a t e ,a n dt h e n
incubated with different amounts of UCH L1 recombinant protein
(Boston Biochem) The reactions were stopped by adding equal
volumes of 26SDS sample loading buffer followed by Western blot
analysis with mouse b-catenin antibody (BD Pharmingen).
Ubiquitin-AMC assay
Overexpressed HA-UCH L1s were immunoprecipitated with
HA antibody from 293 cells transfected with wild type, C90S and
H161D uch l1 expression vectors. Immunoprecipitates were
incubated with 1 mM of ubiquitin-AMC in reaction buffer
containing 50 mM Tris pH 7.5, 2 mM ATP, and 2 mM DTT
for 30 min at 37uC. Samples in triplicate were excited by exposure
to light at a wavelength of 340 nm, and emission was measured at
460 nm.
Stable cell lines
For the establishment of UCH L1 siRNA and control siRNA
stable lines, 293 cells were transfected with 2 mg of respective
plasmid using the Fugene HD (Roche Diagnostics). Cells were
passaged 24 h post transfections and selection was started 48 h
post transfections. The cells were always maintained in the
selective media containing 2 mg/ml puromycin (InvivoGen).
Transient transfections and Luciferase reporter assay
Cells were transiently transfected with total 2 mg of DNA with
Fugene HD reagent (Roche Diagnostics) according to the
manufacturer’s instructions. Cells were collected 48 h post
transfections.
For Luciferase reporter assay, cells were plated in 6-well plates
and transiently transfected with the use of Fugene with TCF
reporter plasmids, TOPFlash or FOPFlash or Uchl1p-Luc
promoter plasmid, and the effector plasmid. The total amount
of DNA in all transfection was kept constant with empty vector.
Luciferase activities were monitored in cell lysates with the use of
Luciferase assay reagents (Promega) 48 h post transfections as
described by the manufacturer. All reporter assay results presented
here are from three independent experiments prepared in
triplicate and have been normalized for b-Gal activity.
Reverse Transcriptase PCR
HEK 293 and NIH 3T3 cells were treated with 25 mM LiCl for
24 h. Total RNA was extracted with the use of Agilent’s Total
RNA isolation mini kit (Agilent Technologies). 500 ng of total
RNA were used to perform RT-PCR reactions with Qiagen’s one
step RT-PCR kit (Qiagen) as per manufacturer’s instructions at an
annealing temperature of 55uC. The samples were analyzed on
1% agarose gel. Primers used:
UCH L1: 59-GGATGGCCACCTCTATGAAC-39,5 9-
AGACCTTGGCAGCGTCCT-39, GAPDH: 59-AGGTGAA-
GGTCGGAGTCAACG-39,5 9-AGGGGTCATTGATGGCAA-
CA-39.
Quantitative Real Time PCR
NIH 3T3 cells were treated with 25 mM LiCl for 6 h and RNA
was isolated. Reverse transcription reaction was performed with
500 ng of total RNA using the iScript cDNA synthesis kit (Bio-
Rad). A 1:25 dilution of cDNA was used in the QRT PCR
reaction. QRT-PCR was carried out in a 15 ml reaction mixture
with gene-specific primers for UCH L1 and GAPDH (also used in
Catenin/TCF and UCH L1
PLoS ONE | www.plosone.org 8 June 2009 | Volume 4 | Issue 6 | e5955RT-PCR) using iQ-SYBR green kit (Bio-Rad). The PCR
conditions were 95uC for 3 min, and 45 cycles of 95uC for 15 s,
55uC for 45 s on the ABI HT 7600 PCR instrument. All samples
were assayed in triplicate. The differences in expression of UCH
L1 were evaluated using a relative quantification method where
the expression of UCH L1 was normalized to the reference gene
GAPDH.
Chromatin Immunoprecipitation
ChIP assay was carried out using Active Motif ChIP-IT
enzymatic kit. KR4 and 293 cells were fixed with 37%
formaldehyde for 10 min at 37uC, the reaction was stopped with
cold 0.125 M Glycine solution for 5 min at RT. The cells were
then washed twice with PBS and collected in 0.5 ml of Digestion
buffer with protease inhibitors. Chromatin with sheared with
shearing enzyme for 10 min at 37uC to obtain an average of 200–
1000 bp fragments. Sheared chromatin was incubated overnight
at 4uC with Protein G magnetic beads, sheared chromatin, TCF4
antibody (Upstate, Clone 6H53). Immunoprecipitation was
performed as per the manufacturer’s instructions, cross-linking
was reversed by incubated the immunoprecipitated complexes
with 5 M NaCL for 2 h at 65uC followed by Proteinase-K
treatment for 2 h at 42uC. PCR reaction was performed with 5 ml
precipitated DNA using the primer pairs flanking consensus TCF
sites in UCH L1 promoter. PCR conditions: one cycle, 95uC for
2 min; 30 cycles of 95uC for 30 s, 55uC for 30 s, and 72uC for
2 m, and a final extension at 72uC for 10 min. The primers used
in the reaction are: Site 1 (59 CATTTACATTCATTCGTATT
39,5 9 CCTTTCACCATCCCAATTAC 39) and Site 2 (59
ATGGGTTTCCAGAAACTTCG 39,5 9 TGGTTGTGGA-
GACGGGATTT 39).
Site Directed Mutagenesis
The UCH L1 promoter was mutated at different TCF4/Lef1
binding sites using the Quik-Change Site Directed Mutagenesis
Kit (Stratagene). The TCF4/Lef1 binding site ‘‘TTTGA’’ was
mutated to ‘‘CCTTG’’ and exactly same mutations were
introduced at both the binding sites. Four nucleotide changes
were introduced into the parental plasmid by oligonucleotide
primers carrying the specific mutations. The promoter was
mutated at a single TCF4/Lef1 binding site or both binding sites
at a time. The parental DNA template was then digested with
DpnI. All mutations and the integrity of the remainder of the
promoter were confirmed by DNA sequencing.
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